top of page

Can a chewing gum treat oral cancer?

5 minutes ago
2 min read

Gum bioengineered to treat oral cancer shown in a lab dish
A bioengineered bean gum has been found to reduce the levels of three microbes associated with head and neck cancers. (Image credit – Kevin Monko/Penn Dental Medicine)

CANCER DIGEST – Nov. 16, 2026 – Researchers at the University of Pennsylvania have developed a chewing gum that effectively eliminates three microbes linked to oral cancers.


The study not only reduced human papilloma virus in lab samples but eliminated two other bacteria linked to cancer, and in contrast to radiation therapy, did not harm beneficial bacteria. The hope is that the chewing gum could treat existing cancer and provide better quality of life for survivors.


The research team led by Henry Daniell, PhD, of Penn Dental Medicine have shown that extracts from the bioengineered chewing gum they developed from lablab beans, contains a natural antiviral protein, called FRIL. The protein has been shown in laboratory experiments to kill three microbes linked to cancer, the virus HPV and two bacterial species, Porphyromonas gigivalis (Pg) and Fusobacterum nucleate (Fn) which are also linked to oral cancers.


As Daniell noted in a press release, current treatments have not significantly improved quality of life or five-year survival. Consequently, Daniell’s team began looking for ways to improve treatment outcomes and quality of life for survivors more than a dozen years ago.


The current study published Feb. 9, 2026  in the journal Scientific Reports found that the bean gum extracts reduced HPV levels by 93% in saliva samples and 80% of oral rinse samples collected from people with oral cancers, and reduced levels of Pg and Fn to near zero without affecting beneficial bacteria normally found in the mouth.


Head and neck cancers primarily occur in the squamous cells that commonly line the mouth and throat as well as other tissues in the body. Head and neck squamous cell carcinoma (HNSCC) is increasing worldwide and often has poor outcomes.


"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said in a press release. "Our findings support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission."


HPV has multiple variants that have been linked to genital cancers and some oral cancers. The HPV vaccine given in childhood are effective in preventing infection by certain types of human papillomavirus. Available vaccines protect against HPV type 16 and 18 that cause the greatest risk of cervical cancer. It is estimated that they may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and possibly some mouth cancers.


While the vaccine can prevent new HPV infections it does not treat existing infections or diseases such as cancer. Treating oral cancers generally involves surgery, radiation and chemotherapy. However radiation therapies often kill beneficial bacteria in the oral cavity, which leads to mouth sores, dry mouth, changes in taste and difficulty swallowing.


With these new study results, Daniell’s team is calling for moving the chewing gum to clinical trials as added therapy with current treatments or as prevention of further infection and transmission.


Source: University of Pennsylvania Penn Today press release and Scientific Reports

Comments


Recent Posts
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

© 2009 to 2014 by Medical Digest Publications • 6125 NE 175th ST. Ste. N103, Kenmore, WA 98028 • 206•499•3479   •   Proudly created with Wix.com

bottom of page